Cystic Fibrosis
1,360
84
121
931
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Published Results
292 trials with published results (21%)
Research Maturity
931 completed trials (68% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
7.9%
107 terminated out of 1360 trials
89.7%
+3.2% vs benchmark
16%
221 trials in Phase 3/4
31%
292 of 931 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 931 completed trials
Clinical Trials (1360)
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis
Markers of Osteoporosis in Cystic Fibrosis
Pathogenicity of Species of the Achromobacter Genus in Patients From Reunion Island With Cystic Fibrosis
Exercise in People With Cystic Fibrosis on CFTR Modulator Therapy
Effect of Losartan in Cystic Fibrosis (CF)-NIH Grant #133240
Natural History of Noncirrhotic Portal Hypertension
Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older
Effects of AD on VI in Patients With CF
Intrapulmonary Percussive Ventilation for Sputum Induction in Adults With Cystic Fibrosis
IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy
The PROMISE Pediatric Study 6 to 11 Years Old
Role of Genetic Factors in the Development of Lung Disease
Genetic Disorders of Mucociliary Clearance in Nontuberculous Mycobacterial Lung Disease
Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders
Increase Tolerance for Exercise and Raise Activity Through Connectedness Trial
Impact of Sinus Surgery on Individuals With Cystic Fibrosis
Maralixibat in Patients With Cystic Fibrosis and Constipation
Glycerol Phenylbutyrate Corrector Therapy For CF (Cystic Fibrosis)